The Journal of Allergy and Clinical Immunology publishes an interesting study on the ability of mannan-conjugated allergoids to reprogram human monocytes towards tolerogenic dendritic cells. 

Mannan-conjugated allergoids represent a new generation of allergy vaccines targeting dendritic cells developed by INMUNOTEK. These cells play a key role in the generation of the cells (Treg cells) responsible for allergen-specific tolerance in allergic patients receiving allergen immunotherapy.

Previous studies had demonstrated the ability of allergoid-mannan conjugates for the generation of Treg cells from the induction of tolerogenic dendritic cells. Now this study demonstrates that such an induction can also be performed from monocytes, the cells that reach at the site of vaccine injection.

This study has been carried out at the Department of Biochemistry, Faculty of Chemistry, Universidad Complutense de Madrid, with the collaboration of the Institute of Biomedicine and Translational Medicine, University of Tartu (Estonia) and INMUNOTEK.

+info